Join ASHM
Join ASHM

Post-Exposure Prophylaxis after non-occupational and occupational exposure to HIV 

Australian National Guidelines (Third Edition)

Download Guidelines

Last Updated: June 2023

Further Information

References

  1. Palich R, Martin-Blondel G, Cuzin L, et al. Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM). Sex Transm Infect 2017;93:493-8.
  2. Gianacas C, Down I, Ellard J, et al. Experiences of HIV: The Seroconversion Study Final Report 2007–2015. Monograph, The Kirby Institute, UNSW Australia; 2015.
  3. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-73.
  4. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771-5.
  5. Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. Aids 2000;14:1864-6.
  6. Bourry O, Brochard P, Souquiere S, et al. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. Aids 2009;23:447-54.
  7. Irvine C, Egan KJ, Shubber Z, Van Rompay KK, Beanland RL, Ford N. Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies. Clin Infect Dis 2015;60 Suppl 3:S165-9.
  8. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. Aids 2005;19:1289-97.
  9. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012;366:2368-79.
  10. Tomkins S, Ncube F. Occupationally acquired HIV: international reports to December 2002. Euro Surveill 2005;10:E050310.2.
  11. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1485-90.
  12. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004;35:519-25.
  13. Poynten IM, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. Aids 2009;23:1119-26.
  14. Mitchell H, Furegato M, Hughes G, Field N, Nardone A. What are the characteristics of, and clinical outcomes in men who have sex with men prescribed HIV postexposure prophylaxis following sexual exposure (PEPSE) at sexual health clinics in England? Sex Transm Infect 2017;93(3):207-13.
  15. Beymer MR, Kofron RM, Tseng CH, et al. Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. Int J STD AIDS 2018;29:557-62.
  16. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41:1507-13.
  17. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr 2008;47:494-9.
  18. Johnson KA, Chen MJ, Kohn R, et al. Acute HIV at the time of initiation of pre-exposure or post-exposure prophylaxis: impact on drug resistance and clinical outcomes. J Acquir Immune Defic Syndr 2021;87:818-25.
  19. Do AN, Ciesielski CA, Metler RP, Hammett TA, Li J, Fleming PL. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol 2003;24:86-96.
  20. Hawkins DA, Asboe D, Barlow K, Evans B. Seroconversion to HIV-1 following a needlestick injury despite combination post-exposure prophylaxis. J Infect 2001;43:12-5.
  21. Woode Owusu M, Wellington E, Rice B, et al. Eye of the Needle United Kingdom surveillance of significant occupational exposures to bloodborne viruses in healthcare workers: data to end 2013. December 2014. Public Health England, London. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/385300/EoN_2014_-_FINAL_CT_3_sig_occ.pdf (last accessed 11 March 2023).
  22. Beltrami EM, Luo CC, de la Torre N, Cardo DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002;23:345-8.
  23. Kijak GH, Kim JH. Timing, adherence, resistance, and … persistence? new insight into the mechanisms of failure of HIV type 1 postexposure prophylaxis. J Infect Dis 2013;208:1542-4.
  24. Jain S, Mayer KH. Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. Aids 2014;28:1545-54.
  25. Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis 2015;60 Suppl 3:S170-6.
  26. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000;355:722-3.
  27. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59:354-9.
  28. McAllister J, Read P, McNulty A, Tong WW, Ingersoll A, Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014;15:13-22.
  29. Boyce JM. Update on hand hygiene. Am J Infect Control 2013;41(5 Suppl):S94-6.
  30. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375:830-9.
  31. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393:2428-38.
  32. Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018;5:e438-e447.
  33. Smith P, Buttenheim A, Schmucker L, Bekker LG, Thirumurthy H, Davey DLJ. Undetectable = Untransmittable (U = U) messaging increases uptake of HIV testing among men: results from a pilot cluster randomized trial. AIDS Behav 2021;25:3128-36.
  34. Calabrese SK, Mayer KH, Marcus JL. Prioritising pleasure and correcting misinformation in the era of U=U. Lancet HIV 2021;8:e175-e180.
  35. HIV exposure through contact with body fluids. Prescrire Int 2012;21(126):100-1, 103-5.
  36. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009;9:118-29.
  37. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. Aids 2010;24:907-13.
  38. del Romero J, Marincovich B, Castilla J, et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. Aids 2002;16:1296-7.
  39. Rothenberg RB, Scarlett M, del Rio C, Reznik D, O’Daniels C. Oral transmission of HIV. Aids 1998;12:2095-105.
  40. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med 1993;153:1451-8.
  41. Richman KM, Rickman LS. The potential for transmission of human immunodeficiency virus through human bites. J Acquir Immune Defic Syndr (1988) 1993;6:402-6.
  42. Cresswell FV, Ellis J, Hartley J, Sabin CA, Orkin C, Churchill DR. A systematic review of risk of HIV transmission through biting or spitting: implications for policy. HIV Med 2018;19:532-40.
  43. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988;259:55-8. Erratum in: JAMA 1989;262:502.
  44. Baggaley RF, Owen BN, Silhol R, et al. Does per-act HIV-1 transmission risk through anal sex vary by gender? An updated systematic review and meta-analysis. Am J Reprod Immunol 2018;80:e13039.
  45. Webb R. Needlestick injuries, discarded needles and the risk of HIV transmission. A research briefing. aidsmap June 2019. Available at: https://www.aidsmap.com/about-hiv/needlestick-injuries-discarded-needles-and-risk-hiv-transmission#:~:text=%22There%20are%20no%20documented%20cases,discarded%20in%20a%20public%20place.%22 (last accessed 10 March 2023).
  46. Callander D, Mooney-Somers J, Keen P, et al. Australian ‘gayborhoods’ and ‘lesborhoods’: a new method for estimating the number and prevalence of adult gay men and lesbian women living in each Australian postcode. Int J Geographic Inform Sci 2020;34:2160-76.
  47. Bui H, Zablotska-Manos I, Hammoud M, et al. Prevalence and correlates of recent injecting drug use among gay and bisexual men in Australia: Results from the FLUX study. Int J Drug Policy 2018;55:222-30.
  48. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2021. Sydney: Kirby Institute, UNSW Sydney; 2022. Available at: https://kirby.unsw.edu.au/report/asr2021 (last accessed 10 March 2023).
  49. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: https://kirby.unsw.edu.au/report/asr2018 (last accessed 10 March 2023).
  50. Ford, N, Venter F, Irvine C, Beanladn R, Shubber Z. Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review. Clin Infect Dis 2015;60:S182-6.
  51. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4.
  52. Australian Register of Therapeutic Goods (ARTG) [internet]. June 2021. Available at: https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg (last accessed 11 March 2023).
  53. Trezza CR, Kashuba AD. Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet 2014;53:611-24.
  54. Podany AT, Scarsi KK, Pham MM, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review. Clin Pharmacokinet 2020;59:1085-107.
  55. Leal L, León A, Torres B, et al. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother 2016;71:1987-93.
  56. Mulka L, Annandale D, Richardson C, Fisher M, Richardson D. Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug-drug interactions (DDIs) with improved adherence and tolerability. Sex Transm Infect 2016;92:107.
  57. Quah SP, McIntyre M, Wood A, Mc Mullan K, Rafferty P. Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure. HIV Med 2021;22:e5-e6.
  58. Urbina AE, McGowan JP, Fine SM, et al. Selecting an initial ART regimen. Table 9: Recommended dose adjustments for use of selected fixed-dose combination antiretroviral medications in patients with hepatic or renal impairment [Internet]. Baltimore (MD): Johns Hopkins University; August 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK559632/table/nycgartreg.T.recommended_dose_adjustment/?report=objectonly (last accessed 15 March 2023).
  59. Inciarte A, Leal L, González E, et al. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. J Antimicrob Chemother 2017;72:2857-61.
  60. Valin N, Fonquernie L, Daguenel A, et al. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis. BMC Infect Dis 2016;16:718.
  61. Mayer KH, Jones D, Oldenburg C, et al. Optimal HIV postexposure prophylaxis regimen completion with single tablet daily elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine compared with more frequent dosing regimens. J Acquir Immune Defic Syndr 2017;75:535-9.
  62. Foster R, McAllister J, Read TR, et al. Single-tablet emtricitabine-rilpivirine-tenofovir as hiv postexposure prophylaxis in men who have sex with men. Clin Infect Dis 2015;61:1336-41.
  63. Chauveau M, Billaud E, Bonnet B, et al. Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. J Antimicrob Chemother 2019;74:1021-7.
  64. Dineen-Griffin S, Garcia-Cardenas V, Rogers K, Williams K, Benrimoj SI. An Australian minor ailments scheme. Evaluation of an integrated approach by community pharmacists and general medical practitioners. October 2019. Available at: https://www.uts.edu.au/sites/default/files/2019-11/Full%20Report%20%28wl%29.pdf (last accessed 12 March 2023).
  65. McAllister JW, Towns JM, McNulty A, et al. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. Aids 2017;31:1291-5.
  66. Hughes C. Renal adverse drug reactions. Curr Opin HIV AIDS 2021;16:303-8.
  67. Saad M, Casado-Castillo F, Kelly P. Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient. Medicine (Baltimore) 2019;98:e15149.
  68. Therapeutic Goods Administration (TGA). Australian product information for TIVICAY dolutegravir (as sodium) 50 mg film-coated tablet [internet]. Available at: https://www.tga.gov.au/sites/default/files/2022-08/auspar-tivicay-tivicay-pd-220705-pi.pdf (last accessed 10 March 2023).
  69. Therapeutic Goods Administration (TGA). Australian product information for ISENTRESS® and ISENTRESS HD® (raltegravir potassium) tablets [internet]. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2010-PI-03893-3&d=20220919172310101 (last accessed 11 March 2023).
  70. Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen. J Microbiol Immunol Infect 2016;49:286-8.
  71. Attardo S, Musumeci O, Velardo D, Toscano A. Statins neuromuscular adverse effects. Int J Mol Sci 2022;23:8364.
  72. Song IH, Zong J, Borland J, et al. The Effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr 2016;72:400-7.
  73. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014;59:e96-138.
  74. Smith DK, Switzer WM, Peters P, et al. A strategy for PrEP clinicians to manage ambiguous HIV test results during follow-up visits. Open Forum Infect Dis 2018;5:ofy180.
  75. World Health Organization (WHO). Delivering HIV test results and messages for re-testing and counselling in adults. Geneva: World Health Organization; 2010. Available at: https://www.ncbi.nlm.nih.gov/books/NBK310688/ (last accessed 10 March 2023).
  76. Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008;3:10-5.
  77. de Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology. Clin Infect Dis 2016;63:555-61.
  78. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999;130:37-9.
  79. Puro V, Calcagno G, Anselmo M, et al. Transient detection of plasma HIV-1 RNA during postexposure prophylaxis. Infect Control Hosp Epidemiol 2000;21:529-31.
  80. Jamani S, Gulholm T, Poynten IM, Templeton DJ. Timing and frequency of chlamydia and gonorrhoea testing in a cross-sectional study of HIV postexposure prophylaxis recipients. Sex Transm Infect 2013;89:604-6.
  81. de Vrieze NH, van Rooijen MS, van de Loeff MS, de Vries HJ. Additional gonorrhea and Chlamydia infections found with rapid follow-up screening in men who have sex with men with an indication for HIV postexposure prophylaxis. Sex Transm Dis 2014;41:515-7.
  82. Moorman AC, de Perio MA, Goldschmidt R, et al. Testing and clinical management of health care personnel potentially exposed to hepatitis C virus. CDC Guidance, United States, 2020. MMWR Recomm Rep 2020;69:1-8.
  83. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet 2019;394:1451-66.
  84. Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. Curr Opin Infect Dis 2019;32:31-7.
  85. Ward E, Carlisle N, Williams E, Heath SL, Meloun K, Walter LA. Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis. J Viral Hepat 2022;29:487-92.
  86. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis 2018;218:16-25.
  87. Black KI, Hussainy SY. Emergency contraception: oral and intrauterine options. Aust Fam Physician 2017;46:722-6.
  88. Hodel EM, Marzolini C, Waitt C, Rakhmanina N. Pharmacokinetics, placental and breast milk transfer of antiretroviral drugs in pregnant and lactating women living with HIV. Curr Pharm Des 2019;25:556-76.
  89. Tenofovir. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  90. Emtricitabine.  Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  91. Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother 2015;70:1928-41.
  92. Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med 2019;16:e1002895.
  93. Raltegravir.  Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  94. Australian Register of Therapeutic Goods (ARTG) information for CIPLA TENOFOVIR + EMTRICITABINE 300/200 Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg tablet bottle pack. Available at: https://www.tga.gov.au/resources/artg?keywords=tenofovir+emtricitabine (last accessed 10 March 2023).
  95. Krishna R, Rizk ML, Larson P, Schulz V, Kesisoglou F, Pop R. Single- and multiple-dose pharmacokinetics of once-daily formulations of raltegravir. Clin Pharmacol Drug Dev 2018;7:196-206.
  96. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988;148:945-9.
  97. Grulich AE, Bavinton BR. Scaling up preexposure prophylaxis to maximize HIV prevention impact. Curr Opin HIV AIDS 2022;17:173-8.
  98. Grulich AE, Jin F, Bavinton BR, et al. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV 2021;8:e486-e494.
  99. Molina JM, Ghosn J, Assoumou L, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV 2022;9:e554-e562.
  100. Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV 2015;2:e512-e519.
  101. Cottrell ML, Yang KH, Prince HM, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis 2016;214:55-64.
  102. Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses 2013;29:1443-50.
  103. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53-60.
  104. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237-46.
  105. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4:151ra125.
  106. Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses 2016;32:32-43.
  107. Callander D, Wiggins J, Rosenberg S, et al. The 2018 Australian trans and gender diverse sexual health survey. Report of findings. The Kirby Institute, UNSW Sydney: Sydney; 2019. Available at: https://kirby.unsw.edu.au/sites/default/files/kirby/report/ATGD-Sexual-Health-Survey-Report_2018.pdf (last accessed 10 March 2023).
  108. Freestone J, Mooney-Somers J, Hudson S. The sector is ready, and the community needs Australian alcohol and other drug treatment services to ask about sexuality and gender identity. Drug Alcohol Rev 2022;41:39-42.
  109. Costa AB, Viscardi LH, Feijo M, Fontanari AMV. HIV voluntary counseling and testing (VCT-HIV) effectiveness for sexual risk-reduction among key populations: a systematic review and meta-analysis. EClinicalMedicine 2022;52:101612.
  110. Zilkens RR, Smith DA, Kelly MC, Mukhtar SA, Semmens JB, Phillips MA. Sexual assault and general body injuries. A detailed cross-sectional Australian study of 1163 women. Forensic Sci Int 2017;279:112-20.
  111. NSW Health. PD2020_006. Responding to Sexual Assault (adult and child) Policy and Procedures. February 2020. Available at: https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2020_006.pdf (last accessed 10 March 2023).
  112. Freedman E. Clinical management of patients presenting following a sexual assault. Aust J Gen Pract 2020;49:406-11.
  113. Fernández I, Lazzari E, Inciarte A, Diaz‐Brito V, Milinkovic A, Arenas‐Pinto A, et al. Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials. HIV Med 2021;22:218-24.
  114. Merchant R, Keshavarz R. Human immunodeficiency virus post-exposure prophylaxis for adolescents and children. Pediatrics 2001;108:e38.
  115. Australian Institute of Health and Welfare (AIHW). The health of Australia’s prisoners 2012. 2013. Available at: https://www.aihw.gov.au/reports/prisoners/health-of-australias-prisoners-2012/contents/table-of-contents (last accessed 14 March 2023). 
  116. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018;391:839-49.  
  117. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393:143-55. 
  118. Gantner P, Hessamfar M, Souala MF, et al. Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. Clin Infect Dis 2020;70:943-6.  
  119. Mayer KH, Gelman M, Holmes J, Kraft J, Melbourne K, Mimiaga MJ. Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure. J Acquir Immune Defic Syndr 2022;90:27-32.  
  120. British Association for Sexual Health and HIV (BASHH). UK guideline for the use of HIV post-exposure prophylaxis. Available at: https://www.bashhguidelines.org/media/1269/pep-2021.pdf (last accessed 10 March 2023). 
  121. Dominguez KL SD, Vasavi T, Crepaz N, et al. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Updated May 2018. Available at: https://stacks.cdc.gov/view/cdc/38856 (last accessed 14 March 2023). 
  122. World Health Organization (WHO). Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2014. Available at: http://apps.who.int/iris/bitstream/handle/10665/145719/9789241508193_eng.pdf;jsessionid=CF1A90A1CD876ED65F80C1F4201B2F15?sequence=1 (last accessed 10 March 2023). 
  123. Australian Bureau of Statistics (ABS). Regional population by age and sex. 2020 [internet]. Release date 2021. Available at: https://www.abs.gov.au/statistics/people/population/regional-population-age-and-sex/2020#data-download (last accessed 10 March 2023). 
  124. Australian Bureau of Statistics (ABS). Estimates of Aboriginal and Torres Strait Islander Australians 2016 [internet]. Release date 2018. Available at: https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-aboriginal-and-torres-strait-islander-australians/jun-2016#data-download (last accessed 10 March 2023). 
  125. Larney S, Hickman M, Guy R, et al. Estimating the number of people who inject drugs in Australia. BMC Public Health 2017;17:757.  
  126. Stephens JH, Gray RT, Guy R, Vickers T, Ward J. A HIV diagnosis and treatment cascade for Aboriginal and Torres Strait Islander peoples of Australia. AIDS Care  2023;35:83-90. 
  127. Marukutira T, Gray RT, Douglass C, et al. Gaps in the HIV diagnosis and care cascade for migrants in Australia, 2013-2017: A cross-sectional study. PLoS Med 2020;17:e1003044. 

Endorsed By

These guidelines are pending endorsement by the Blood Borne Viruses and Sexually Transmitted Infections Standing Committee (BBVSS).

Funded By: The Australian Government Department of Health
Disclaimer: Whilst the Australian Department of Health provides financial assistance to ASHM Health, the material contained in this resource produced by us should not be taken to represent the views of the Australian Department of Health.

The content of this resource is the sole responsibility of ASHM Health.

Sign up for the ASHM Newsletter

Stay up to date with the peak organisation of health professionals in Australia and New Zealand who work in HIV, viral hepatitis, other BBVs and sexually transmissible infections.

Sign Up Now
Facebook Vimeo-v Twitter Linkedin

We acknowledge that ASHM Health offices are located on the land of the Gadigal peoples of the Eora Nation (Sydney Office) and the Turrbal and Jagera/Yuggera peoples (Brisbane Office) who are the Traditional Owners of the lands where both offices are situated. We pay our respects to Elders past and present.

ABN 48 264 545 457 | CFN 17788
Copyright © 2023 ASHM Health

Scroll to Top